Atopic DermatitisFeatured PodcastPodcast Highlights

AD Treatment – The Future Landscape

By April 13, 2021August 23rd, 2022No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

AD Treatment – The Future Landscape

Drs. Amy Paller, Jonathan Silverberg & Adam Friedman

 

Consider this final episode of the 5 part all you can handle Atopic Dermatitis series the world series of dermatitis. Hall of famers Dr.s Amy Paller and Jonathan Silverberg join host Dr. Adam Friedman to review current moderate to severe AD treatment approaches and use of systemic therapies, discuss advancement on AD clinical management with use of novel target therapy, and share clinical experience with the use of biologics treatment. As we have all been thrown a curve ball in life, faculty address the growing concerns surrounding dermatology-related immunosuppressant therapy during the pandemic and how to discuss this issue with patients. Slide into home with a peak at the future therapies landscape in clinical development. The practical peals alone are worth the price of admission (um, it’s free).
Listen Now
Learning Objectives
Upon completion of this podcast participants should be able to:
  • Recognize the impact of target therapeutic in managing moderate to severe AD
  • Consider future treatment strategies that may enhance optimal patient care

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.

Disclosures
Amy Paller, MD – Grant/Research Support: AbbVie, Eli Lilly, Regeneron. Incyte. Consultant: Abbvie, Arena, Bausch, Bristol Myer Squibb, Dermavant, Eli Lilly, Forte, Leo, Lifemax, Pfizer, Rapt, Regeneron, and Sanofi.

Jonathan Silverberg, MD – Grant/Research Support: Galderma, Pfizer. Consultant: Abbvie, Afyx, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi. Speakers’ Bureau: Regeneron, Sanofi-Genzyme, Pfizer, Eli Lilly.

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

You May Also Like

Formulation Foundations: A Peak Behind the Development Curtain

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. David Osborne Finding the right formulation is not always a fun endeavor for the practitioner or patient, and can be the make or break for patient…

Reface the Chase: Paradigm shifts in the AD Management Strategy Mentality

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Raj Chovatiya Who doesn't love a good game of "Whack a Mole?" Anyone? Just as you try to stay ahead of those furry, taunting, smiling devils…

Diving into Dyspigmentation: Discoloration Details and Future Directions

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Andrew Alexis Dyspigmentation is defeating....for the patient and the practitioner as it is often a secondary feature of chronic inflammatory skin diseases and often a greater…

Leave a Reply